BioMarin Pharmaceutical Inc

BMRN 
(NASDAQ) 
 
$ 92.70
Updated 08/12/2018
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 475,662
High $ 96.12
Low $ 91.58
Open $ 94.44
ISIN
Prev close $ 95.54
# of shares 178.06M
Market cap 16,506M USD
Intraday

Market closed
BioMarin Pharmaceutical Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  92.70 -5.2% Stock price decreasing -3.1% Stock price decreasing -4.9% Stock price decreasing 2.3% Stock price increasing 13.1% Stock price increasing
Powered by TradingView

News about BioMarin Pharmaceutical Inc

  • English
  • Regulatory news

Company profile

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
10 December 2018 11:54:09
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB2 - 2018-12-10 12:54:09 - 2018-12-10 11:54:09 - 1000 - Website: OKAY